公开(公告)号：CA2672737A1

公开(公告)日：2008-11-06

申请号：CA2672737

申请日：2007-12-19

Applicant: ABBOTT LAB

Inventor： ANDERSON DAVID D ,  WAGNER ROLF ,  CARRICK ROBERT J ,  ZHANG RONG ,  HE WENPING ,  ROCKWAY TODD W ,  MARING CLARENCE J ,  PILOT-MATIAS TAMI J ,  MASSE SHERIE V L ,  COOPER CURT S ,  BETEBENNER DAVID A ,  MO HONGMEI ,  MOLLA AKHTERUZZAMAN ,  LU LIANGJUN

IPC: A01N43/42 ,  A61K31/44

Abstract: Compounds effective in inhibiting replication of Hepatitis C virus ( HCV ) or other viruses are disclosed. This invention is also directed to composi tions comprising such compounds, coformulation or co-administration of such compounds with other anti-viral or therapeutic agents, processes and interme diates for the syntheses of such compounds, and methods of using such compou nds for the treatment of HCV or other viral infections.

公开(公告)号：NZ569817A

公开(公告)日：2011-10-28

申请号：NZ56981706

申请日：2006-12-20

Applicant: ABBOTT LAB

Inventor： BETEBENNER DAVID A ,  DEGOEY DAVID A ,  MARING CLARENCE J ,  KRUEGER ALLAN C ,  IWASAKI NOBUHIKO ,  ROCKWAY TODD W ,  COOPER CURT S ,  ANDERSON DAVID D ,  DONNER PAMELA L ,  GREEN BRIAN E ,  KEMPF DALE J ,  LIU DACHUN ,  MCDANIEL KEITH F ,  MADIGAN DAROLD L ,  MOTTER CHRISTOPHER E ,  PRATT JOHN K ,  SHANLEY JASON P ,  TUFANO MICHAEL D ,  WAGNER ROLF ,  ZHANG RONG ,  MOLLA AKHTERUZZAMAN ,  MO HONGMEI ,  PILOT-MATIAS TAMI J ,  MASSE SHERIE V L ,  CARRICK ROBERT J ,  HE WEPING ,  LU LIANGJUN ,  GRAMPOVNIK DAVID J

IPC: C07D471/04 ,  A61K31/4375 ,  A61K31/519 ,  A61P31/12

Abstract: Disclosed is a pyrido[2,3-d]pyrimidin-4-yl compound, a tautomer of the compound, or a pharmaceutically acceptable salt of the compound or tautomer, wherein the compound has Formula I, wherein: W1, W2 and W3 are each N, and W4 is C(R33); Z is a bond, -CR41R41'- or -NR41-, wherein R41 and R41 ' are each independently selected from the group consisting of hydrogen, alkyl, alkenyl and alkynyl; A is a carbocyclyl or heterocyclyl, R10 is hydrogen or halogen; R17, R33 and R35, X, R22, R50 are defined in the specification, e.g. 4-(4-Amino-3-methyl-phenoxy)-N-(4-bromo-phenyl)-3-(7-isopropy-1-pyrido[2,3-d]pyrimidin-4-ylamino)-benzamide for the treatment of HCV infection.